Treasure Valley Medical Research

The trials here

What the 19 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)9 trials
• Asthma7 trials
• Gastroparesis1 trial
• Ulcerative colitis1 trial
• Vitiligo1 trial

Phase

• Phase 310 trials
• Phase 27 trials
• Phase 41 trial

Status

• Completed8 trials
• Active, not recruiting7 trials
• Recruiting2 trials
• Enrolling by invitation1 trial
• Not yet recruiting1 trial

Lead sponsor

• Amgen3 trials
• Eli Lilly and Company3 trials
• Incyte Corporation2 trials
• Regeneron Pharmaceuticals2 trials
• Teva Branded Pharmaceutical Products R&D LLC2 trials
• and 6 more

Running trials

• Recruiting

  A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

  NCT07783425· Phase 3· Pfizer· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

  Contact: Neetu Talreja (principal investigator)

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

  NCT06832618· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

  NCT06966479· Phase 2· Upstream Bio Inc.· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study of Barzolvolimab in Patients With Atopic Dermatitis

  NCT06727552· Phase 2· Celldex Therapeutics· Source

• Active, not recruiting

  Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

  NCT06572228· Phase 4· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

  NCT05509023· Phase 2· Q32 Bio Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)2 recruiting
• Ulcerative colitis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

  NCT06899217· Phase 2· CinDome Pharma, Inc.· Source

• Completed

  A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

  NCT06664619· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  A Study to Evaluate Solriktug in Adult Participants With Asthma

  NCT06496607· Phase 2· Uniquity One (UNI)· Source

• Completed

  A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

  NCT06224192· Phase 3· Amgen· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

  NCT06196879· Phase 2· Upstream Bio Inc.· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

  NCT05398445· Phase 3· Amgen· Source

• Completed

  Registry of Asthma Patients Initiating DUPIXENT®

  NCT04287621· Regeneron Pharmaceuticals· Source